Hematologic Malignancies/Pediatric Malignancies. III. Treatment of Relapsed/Refractory Multiple Myeloma
Murakami, H.; Saitoh, T.; Kasamatsu, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(5): 539-544
2016
ISSN/ISBN: 0385-0684 PMID: 27344682 Document Number: 689460
Document emailed within 1 workday
Related Documents
Usui, N. 2019: Hematologic Malignancies/Pediatric Malignancies Current Guidelines of Clinical Management and Drug Therapy for Hematological Malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(5): 859-861Usui, N. 2017: Hematologic Malignancies/Pediatric Malignancies Acute Leukemia - Current Treatment and Future Perspective Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(5): 378-379
Usui, N. 2011: Hematologic malignancies/ pediatric malignancies-chronic myeloid leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 744
Usui, N. 2009: Hematologic malignancies/pediatric malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(5): 742-743
Yuan, Z.-g.; Hou, J.; Wang, D.-x.; Fu, W.-j.; Chen, Y.-b.; Xi, H. 2008: Bortezomib-based combination therapy for relapsed or refractory multiple myeloma Zhonghua Nei Ke Za Zhi 47(2): 102-106
Dadacaridou, M.; Papanicolaou, X.; Maltesas, D.; Megalakaki, C.; Patos, P.; Panteli, K.; Repousis, P.; Mitsouli-Mentzikof, C. 2007: Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients Journal of BUON: Official Journal of the Balkan Union of Oncology 12(1): 41-44
Baltz, J.K.; Montello, M.J. 1993: Cladribine for the treatment of hematologic malignancies Clinical Pharmacy 12(11): 805
Shah, J.J. 2013: Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib Oncology 27 Suppl. 3: 19-23
Gutterman, J.U. 1988: The role of interferons in the treatment of hematologic malignancies Seminars in Hematology 25(3 Suppl 3: 3-8
Champlin, R. 1991: Immunobiology of bone marrow transplantation as treatment for hematologic malignancies Transplantation Proceedings 23(4): 2123-2127
Nagura, E.; Kawashima, K. 1986: Secondary malignancies associated with hematological malignancies following anticancer treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(4 Part 2): 1464-1474
Nenova, I.S.; Goranov, S.E.; Mateva, N.G.; Ananoshtev, N.H. 2003: Treatment with fluorated quinolones of febrile neutropenia in patients with hematologic malignancies Folia Medica 45(1): 13-19
Velez-Yanguas, M.C.; Warrier, R.P. 1996: The evolution of chemotherapeutic agents for the treatment of pediatric musculoskeletal malignancies Orthopedic Clinics of North America 27(3): 545-549
Wierda, W.G.; Kipps, T.J. 2000: Gene therapy of hematologic malignancies Seminars in Oncology 27(5): 502-511
Nara, N. 2002: Molecular diagnosis in hematologic malignancies Rinsho Byori. Japanese Journal of Clinical Pathology 50(4): 331-336
San-Miguel, J.F.; Bartram, C.; Campana, D.; Andreeff, M. 1994: Minimal residual disease in hematologic malignancies Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion Suppl: 147-152
Ueoka, H.; Ueno, K.; Yamane, T.; Toyoda, K.; Endo, H.; Nishihara, R.; Takahashi, I.; Ohnoshi, T.; Kitajima, K.; Kimura, I. 1983: Phase Ii study of mitoxantrone for hematologic malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 10(11): 2399-2402
Keating, M.J.; O'Brien, S.; Plunkett, W.; Robertson, L.E.; Gandhi, V.; Estey, E.; Dimopoulos, M.; Cabanillas, F.; Kemena, A.; Kantarjian, H. 1994: Fludarabine phosphate: a new active agent in hematologic malignancies Seminars in Hematology 31(1): 28-39
deMagalhaes-Silverman, M.; Bloom, E.J.; Donnenberg, A.; Lister, J.; Pincus, S.; Rybka, W.B.; Ball, E.D. 1996: Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies Bone Marrow Transplantation 17(3): 329-333
Hernández, J.A.; Martino, R.; Pericas, R.; Sureda, A.; Brunet, S.; Domingo-Albós, A. 1998: Achromobacter xylosoxidans bacteremia in patients with hematologic malignancies Haematologica 83(3): 284-285